Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)

Details for Australian Patent Application No. 2006320654 (hide)

Owner Nevada Cancer Institute

Inventors Ma, Yupo

Agent Freehills

Pub. Number AU-A-2006320654

PCT Pub. Number WO2007/064696

Priority 60/741,015 29.11.05 US

Filing date 29 November 2006

Wipo publication date 7 June 2007

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

Event Publications

12 June 2008 PCT application entered the National Phase

  PCT publication WO2007/064696 Priority application(s): WO2007/064696

27 October 2011 Assignment before Grant

  Nevada Cancer Institute The application has been assigned to Ma, Yupo

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006320655-Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity

2006320646-Prepregs and cured in place solid surfaces prepared therefrom